ASP Isotopes Inc. — Form 10-K Summary
Business context and reporting period
Annual report for the year ended December 31, 2023, filed April 10, 2024. ASP Isotopes is a development-stage advanced materials company developing isotope-enrichment technologies, principally the Aerodynamic Separation Process and Quantum Enrichment. Initial target products include Carbon-14, Molybdenum-100 and Silicon-28, with longer-term ambitions in HALEU, Lithium-6 and other isotopes.
The company operates primarily in South Africa and managed one operating segment in 2023. It acquired a 51% interest in PET Labs Pharmaceuticals in October 2023, adding limited downstream radiopharmacy operations and the company’s first reported operating revenue. Two operating segments are planned for 2024: nuclear fuels and specialist isotopes and related services.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $433,026 | $0 |
| Cost of goods sold | $294,056 | $0 |
| Gross profit | $138,970 | $0 |
| Gross margin | 32.1% | Not meaningful |
| Research and development expense | $764,581 | $1,273,536 |
| Selling, general and administrative expense | $15,416,388 | $3,825,512 |
| Net loss attributable to ASP shareholders | $16,286,234 | $4,945,139 |
| Basic and diluted loss per share | $0.49 loss | $0.18 loss |
| Cash at year-end | $7,908,181 | $2,389,140 |
| Net cash used in operating activities | $5,412,392 | $2,939,893 |
| Net cash used in investing activities | $2,453,191 | $4,473,164 |
| Net cash provided by financing activities | $13,385,491 | $6,641,052 |
| Total liabilities | $8,711,282 | $2,678,804 |
| Accumulated deficit | $23,839,300 | $7,553,066 |
Stock-based compensation was $8.7 million in 2023, including $8.4 million in selling, general and administrative expense and $0.4 million in research and development expense. The company reported no bank debt at year-end, although it had $470,396 of current notes payable and $269,033 of finance lease liabilities. Other current liabilities included the $1.5 million balance payable for the PET Labs acquisition.
Material changes versus the prior comparable period
- Revenue began following the PET Labs acquisition, with activity included for approximately two months. The filing’s results table reports $433,026 of revenue, while a revenue note refers to $443,026; the filing text does not provide a clear reconciled value.
- Net loss increased to $16.3 million from $4.9 million, primarily due to substantially higher public-company, corporate, personnel and stock-based compensation costs.
- SG&A increased to $15.4 million from $3.8 million, while R&D decreased to $0.8 million from $1.3 million.
- Operating cash use increased to $5.4 million from $2.9 million. Financing inflows increased principally because of 2023 equity offerings generating $13.6 million of net proceeds.
- Property and equipment increased to $10.7 million, including $9.1 million of construction in progress, as the company continued building enrichment facilities in Pretoria.
- Common shares outstanding increased to 48.9 million from 35.9 million, reflecting equity financing and other share issuances.
Outlook, liquidity, risks and unusual items
- The C-14 facility was commissioned and was expected to be production-ready after installation of essential components. Completion and commissioning of a larger multi-isotope Pretoria facility was anticipated in mid-2024.
- The company expects a U.S. highly enriched metal supply contract to generate approximately $9 million of annual sales during 2024. It also has a C-14 tolling arrangement with a minimum take-or-pay amount of approximately $2.5 million annually, supported by a bank letter of guarantee.
- An $882,000 customer prepayment for future Mo-100 and Mo-98 deliveries was recorded as deferred revenue at December 31, 2023.
- The company entered into a 25-year Mo-100 supply arrangement with potential annual value of up to $27 million, but it has not yet produced commercial quantities of isotopes and has no isotope sales revenue.
- Management stated that year-end cash, together with subsequent financing, would not fund operations and capital requirements for more than 12 months from the financial-statement issuance date. The auditor included a going-concern explanatory paragraph, and substantial doubt remains about the company’s ability to continue without additional financing.
- Subsequent to year-end, Quantum Leap Energy raised gross proceeds of approximately $20.5 million through convertible notes, and ASP Isotopes received approximately $5.5 million from warrant exercises. The notes bear interest at 6% for the first year and 8% thereafter, mature in 2029 and may convert at a discount upon a qualifying QLE public transaction.
- The company disclosed material weaknesses in internal control over financial reporting involving control documentation and execution, finance and accounting staffing, and information-technology logical security and privileged access. Disclosure controls and procedures were deemed ineffective at December 31, 2023.
- Key risks include technology and scale-up failure, regulatory and nuclear dual-use restrictions, permitting delays, dependence on limited suppliers and customers, South African electricity and political risks, intellectual-property protection, dilution from future financing and continued operating losses.
- No material legal proceedings were pending. A prior intellectual-property dispute involving NMS and Radfarma was resolved through a mutual release without payment or licensing of rights.
Most important facts for investors to verify
- Whether the enrichment facilities achieved commercial-scale production and whether the mid-2024 commissioning targets were met.
- Actual 2024 revenue, including fulfillment of the $9 million supply contract and C-14 take-or-pay arrangement.
- Reconciliation of the filing’s conflicting $433,026 and $443,026 revenue disclosures.
- Current cash runway, additional capital needs and the terms, conversion mechanics and guarantees associated with QLE’s convertible notes.
- Progress toward remediation of the disclosed internal-control material weaknesses.
- Regulatory approvals required for C-14, Mo-100, HALEU and other products, including approvals for customer use of Mo-100-derived medical isotopes.
- Whether the ASP and Quantum Enrichment technologies have demonstrated commercial-scale performance, since the filing states that commercial isotope production had not yet been demonstrated.
- Potential dilution from outstanding options, warrants, restricted stock and future equity or convertible-debt financings.